Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 5/20 | 0.76 |
| ▸ | HTR2A | P28223 | 9/20 | 0.63 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 5/20 | 0.53 |
| ▸ | HTR2B | P41595 | 5/20 | 0.53 |
| ▸ | HTR1A | P08908 | 3/20 | 0.53 |
| ▸ | DRD1 | P21728 | 1/20 | 0.49 |
| ▸ | HTR1D | P28221 | 1/20 | 0.49 |
| ▸ | HTR1B | P28222 | 1/20 | 0.49 |
| ▸ | HTR1E | P28566 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | HTR5A | P47898 | 1/20 | 0.49 |
| ▸ | CDK4 | P11802 | 1/20 | 0.45 |
| ▸ | CCND1 | P24385 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29967542 | 1.00 | HTR6 (0.76) | HTR6HTR2AMTNR1AMTNR1BHTR2C | |
| Fumaric Acid SCHEMBL30933120 | 0.90 | HTR6 (0.62) | HTR6HTR2AMTNR1AMTNR1BHTR2C | |
| SCHEMBL25244537 | 0.89 | HTR6 (0.70) | HTR6HTR2AMTNR1AMTNR1BHTR2C | |
| SCHEMBL29511845 | 0.88 | HTR6 (0.73) | HTR6HTR2AMTNR1AMTNR1BHTR2C | |
| SCHEMBL4216556 | 0.88 | HTR6 (0.73) | HTR6HTR2AMTNR1AMTNR1BHTR2C | |
| SCHEMBL31560407 | 0.87 | HTR6 (0.57) | HTR6HTR2AMTNR1AMTNR1BHTR2C | |
| Hydrochloric Acid SCHEMBL31397600 | 0.87 | HTR6 (0.71) | HTR6HTR2AMTNR1AMTNR1BHTR2C | |
| SCHEMBL19235737 | 0.86 | HTR6 (1.00) | HTR6HTR2AMTNR1AMTNR1BHTR2C | |
| SCHEMBL29993252 | 0.86 | HTR6 (1.00) | HTR6HTR2AMTNR1AMTNR1BHTR2C | |
| SCHEMBL29758535 | 0.86 | HTR6 (1.00) | HTR6HTR2AMTNR1AMTNR1BHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4618981-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | Remedi, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-4547250-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | Terran Biosciences Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-20 | — | — | US | claimed |
| WO-2024108195-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | REMEDI, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| EP-4313030-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | Terran Biosciences, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2024006984-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2024-01-04 | — | — | WO | claimed |
| WO-2022221942-A1 | PREVENTION OF DRUG DIVERSION | BETTERLIFE PHARMA INC. (CA) | 2022-10-27 | — | — | WO | claimed |
| WO-2022212854-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2022-10-06 | — | — | WO | claimed |
| US-20260108544-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260108493-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | CAAMTECH, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4720030-A1 | ASYMMETRIC PHENYLALKYLAMINES | Alexander Shulgin Research Institute, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260092034-A1 | 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME | KULEON LLC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20210251976-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2021-08-19 | — | — | US | disclosed |
| WO-2021101926-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | STAMETS PAUL EDWARD (US) | 2021-05-27 | — | — | WO | disclosed |
| US-20210145851-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS, LLC | 2021-05-20 | — | — | US | disclosed |
| US-20210069170-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS, LLC | 2021-03-11 | — | — | US | disclosed |
| US-20190142851-A1 | COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID | CAAMTECH, INC. | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190142851-A1 | COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID | CNR1, CNR2, HTR5A | HTR6 10/4885HTR2A 6/4885MTNR1A 315/4885 |
| US-20260092034-A1 | 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME | HTR2C, HTR7, HTR6 | HTR6 3/4885HTR2A 6/4885MTNR1A 75/4885 |
| US-20210251976-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR6 2/4885HTR2A 11/4885MTNR1A 199/4885 |
| US-20210145851-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR6 2/4885HTR2A 11/4885MTNR1A 199/4885 |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | HTR1A, HTR2A, HTR3A | HTR6 10/4885HTR2A 2/4885MTNR1A 82/4885 |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | HTR6 15/4885HTR2A 14/4885MTNR1A 232/4885 |
| US-20260108493-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | ADRA2C, ADRB3, ADRA2B | HTR6 16/4885HTR2A 19/4885MTNR1A 81/4885 |
| US-20210069170-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR6 2/4885HTR2A 11/4885MTNR1A 199/4885 |
| US-20260108544-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR6 2/4885HTR2A 9/4885MTNR1A 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.